contraindications of tirzepatide At a glance factsheet: for management type 2 diabetes Tirzepatide (Mounjaro)

IMPORTANT SAFETY INFORMATION: Tirzepatide has a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA as of April 2025

Prepared peptide solutions have a shorter usable window and should be stored according to the protocol and supplier guidance

New Horizons in Treatment of Osteoporosis

Compounded medications have been customized by licensed pharmacists to meet a need of an individual patient when a commercially available drug cannot